Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.01
NAS:BIOS's Cash to Debt is ranked lower than
97% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 0.32 vs. NAS:BIOS: 0.01 )
Ranked among companies with meaningful Cash to Debt only.
NAS:BIOS' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.47 Max: No Debt
Current: 0.01
Equity to Asset -0.04
NAS:BIOS's Equity to Asset is ranked lower than
94% of the 247 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. NAS:BIOS: -0.04 )
Ranked among companies with meaningful Equity to Asset only.
NAS:BIOS' s Equity to Asset Range Over the Past 10 Years
Min: -0.18  Med: 0.42 Max: 0.75
Current: -0.04
-0.18
0.75
F-Score: 4
Z-Score: 0.09
M-Score: -2.27
WACC vs ROIC
8.15%
-3.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1.14
NAS:BIOS's Operating margin (%) is ranked lower than
80% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 6.81 vs. NAS:BIOS: -1.14 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:BIOS' s Operating margin (%) Range Over the Past 10 Years
Min: -29.29  Med: -0.05 Max: 2.06
Current: -1.14
-29.29
2.06
Net-margin (%) -5.05
NAS:BIOS's Net-margin (%) is ranked lower than
82% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 4.82 vs. NAS:BIOS: -5.05 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:BIOS' s Net-margin (%) Range Over the Past 10 Years
Min: -30.51  Med: -3.77 Max: 9.77
Current: -5.05
-30.51
9.77
ROA (%) -8.68
NAS:BIOS's ROA (%) is ranked lower than
87% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. NAS:BIOS: -8.68 )
Ranked among companies with meaningful ROA (%) only.
NAS:BIOS' s ROA (%) Range Over the Past 10 Years
Min: -44.23  Med: -10.75 Max: 20.26
Current: -8.68
-44.23
20.26
ROC (Joel Greenblatt) (%) -15.78
NAS:BIOS's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 18.74 vs. NAS:BIOS: -15.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:BIOS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -413.83  Med: -6.75 Max: 23.24
Current: -15.78
-413.83
23.24
Revenue Growth (3Y)(%) 6.70
NAS:BIOS's Revenue Growth (3Y)(%) is ranked lower than
55% of the 181 Companies
in the Global Medical Care industry.

( Industry Median: 8.10 vs. NAS:BIOS: 6.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:BIOS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.4  Med: 2.7 Max: 15.9
Current: 6.7
-29.4
15.9
EPS Growth (3Y)(%) 174.70
NAS:BIOS's EPS Growth (3Y)(%) is ranked higher than
98% of the 133 Companies
in the Global Medical Care industry.

( Industry Median: 6.50 vs. NAS:BIOS: 174.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:BIOS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -82.7  Med: -13.8 Max: 502.8
Current: 174.7
-82.7
502.8
» NAS:BIOS's 10-Y Financials

Financials (Next Earnings Date: 2017-03-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

BIOS Guru Trades in Q4 2015

Jim Simons 102,220 sh (New)
Diamond Hill Capital 3,055,476 sh (+2.51%)
Mario Gabelli 864,850 sh (+1.44%)
Pioneer Investments 280,320 sh (unchged)
» More
Q1 2016

BIOS Guru Trades in Q1 2016

Diamond Hill Capital 3,568,829 sh (+16.80%)
Pioneer Investments 280,320 sh (unchged)
Jim Simons Sold Out
Mario Gabelli 839,352 sh (-2.95%)
» More
Q2 2016

BIOS Guru Trades in Q2 2016

Paul Tudor Jones 247,500 sh (New)
Diamond Hill Capital 5,317,224 sh (+48.99%)
Mario Gabelli 904,402 sh (+7.75%)
Pioneer Investments 280,320 sh (unchged)
» More
Q3 2016

BIOS Guru Trades in Q3 2016

Pioneer Investments 280,320 sh (unchged)
Paul Tudor Jones Sold Out
Diamond Hill Capital 5,306,619 sh (-0.20%)
Mario Gabelli 875,102 sh (-3.24%)
» More
» Details

Insider Trades

Latest Guru Trades with BIOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care
Compare:NYSE:QHC, NYSE:CCM, AMEX:HLTH, NYSE:ADPT, NYSE:AAC, NAS:USMD, OTCPK:CATS, OTCPK:BNKL, OTCPK:MIHI, NAS:JYNT, OTCPK:CCEL, OTCPK:FCHS, OTCPK:AMEH, OTCPK:CMBGF, OTCPK:CVHIF, AMEX:AMS, OTCPK:FDNH, OTCPK:CPAI, AMEX:SSY, OTCPK:PFHO » details
Traded in other countries:MM6.Germany,
BioScrip Inc provides home infusion & other home healthcare services to patients, physicians, hospitals, healthcare payors & pharmaceutical manufacturers to provide clinical management solutions & delivers cost-effective access to medications.

BioScrip Inc, formerly known as MIM Corporation, was incorporated in Delaware in 1996. The Company provides home infusion and other home healthcare services to patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivers cost-effective access to prescription medications and home health services. Its services are provided in coordination with, and under the direction of the patient's physicians. The sales and marketing efforts are focused on payors, healthcare systems and physician prescribers and are driven by dedicated managed care and physician sales teams as well as home health care consultants. PBM Services has over 100 relationships with PBM clients, including Medicaid MCOs, employers, TPAs, workers compensation providers and discount card marketers. The Company undertakes direct sales methods to promote the discount card program and add new marketing organizations. The Company owns trademarks, trade names and service marks including BioScrip, BioScrip Infusion Services, BioScrip Medical Supply Services, BioScrip PBM Services, BioScrip Pharmacy Services, Applied Health Care, CarePoint Partners, Critical Homecare Solutions, Deaconess HomeCare, Deaconess Hospice, among others. The Company's competitors within the home infusion market include Walgreen Co., including OptionCare and Critical Care Systems; CVS Caremark Corp., through its recent acquisition of the Coram infusion business; Express Scripts Holding Company through its subsidiary Accredo Health Group; and various regional and local providers of alternate site healthcare services such as hospitals, local home health agencies, and other local providers. In Home Health Services, the Company competes with Gentiva Health Services, Inc., Almost Family, Inc., Amedisys, Inc., LHC Group, Inc., among others. In PBM and Discount Card Services, the competitors include Express Scripts, Inc., Catamaran Corp., and CVS/Caremark Corp.

Ratios

vs
industry
vs
history
P/S 0.11
BIOS's P/S is ranked higher than
97% of the 281 Companies
in the Global Medical Care industry.

( Industry Median: 1.50 vs. BIOS: 0.11 )
Ranked among companies with meaningful P/S only.
BIOS' s P/S Range Over the Past 10 Years
Min: 0.04  Med: 0.2 Max: 1.31
Current: 0.11
0.04
1.31
EV-to-EBITDA 137.57
BIOS's EV-to-EBITDA is ranked lower than
98% of the 251 Companies
in the Global Medical Care industry.

( Industry Median: 14.47 vs. BIOS: 137.57 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -785.6  Med: 12.05 Max: 188.7
Current: 137.57
-785.6
188.7
Current Ratio 1.13
BIOS's Current Ratio is ranked lower than
57% of the 249 Companies
in the Global Medical Care industry.

( Industry Median: 1.29 vs. BIOS: 1.13 )
Ranked among companies with meaningful Current Ratio only.
BIOS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.34 Max: 2.76
Current: 1.13
0.86
2.76
Quick Ratio 0.89
BIOS's Quick Ratio is ranked lower than
69% of the 249 Companies
in the Global Medical Care industry.

( Industry Median: 1.15 vs. BIOS: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
BIOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.16 Max: 2.5
Current: 0.89
0.79
2.5
Days Inventory 17.63
BIOS's Days Inventory is ranked higher than
52% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 18.12 vs. BIOS: 17.63 )
Ranked among companies with meaningful Days Inventory only.
BIOS' s Days Inventory Range Over the Past 10 Years
Min: 10.48  Med: 15.31 Max: 37.85
Current: 17.63
10.48
37.85
Days Sales Outstanding 40.30
BIOS's Days Sales Outstanding is ranked higher than
51% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 42.08 vs. BIOS: 40.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.54  Med: 44.82 Max: 74.62
Current: 40.3
24.54
74.62
Days Payable 24.45
BIOS's Days Payable is ranked lower than
69% of the 162 Companies
in the Global Medical Care industry.

( Industry Median: 38.52 vs. BIOS: 24.45 )
Ranked among companies with meaningful Days Payable only.
BIOS' s Days Payable Range Over the Past 10 Years
Min: 18.26  Med: 22.76 Max: 45.45
Current: 24.45
18.26
45.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.40
BIOS's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 127 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. BIOS: -6.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19.7  Med: -8 Max: -0.5
Current: -6.4
-19.7
-0.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.46
BIOS's Price/Median PS Value is ranked higher than
88% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 1.00 vs. BIOS: 0.46 )
Ranked among companies with meaningful Price/Median PS Value only.
BIOS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 1.07 Max: 6.52
Current: 0.46
0.25
6.52
Earnings Yield (Greenblatt) (%) -2.06
BIOS's Earnings Yield (Greenblatt) (%) is ranked lower than
84% of the 295 Companies
in the Global Medical Care industry.

( Industry Median: 4.17 vs. BIOS: -2.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.06  Med: 2.65 Max: 9.6
Current: -2.06
-2.06
9.6
Forward Rate of Return (Yacktman) (%) -3.86
BIOS's Forward Rate of Return (Yacktman) (%) is ranked lower than
80% of the 110 Companies
in the Global Medical Care industry.

( Industry Median: 10.28 vs. BIOS: -3.86 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIOS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -86.4  Med: -1.9 Max: 5.9
Current: -3.86
-86.4
5.9

More Statistics

Revenue (TTM) (Mil) $939.2
EPS (TTM) $ -0.74
Beta0.73
Short Percentage of Float16.38%
52-Week Range $1.10 - 3.43
Shares Outstanding (Mil)117.68

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 930 970 1,033
EPS ($) -0.29 -0.32 0.05
EPS w/o NRI ($) -0.29 -0.32 0.05
EPS Growth Rate
(3Y to 5Y Estimate)
15.00%
Dividends Per Share ($)
» More Articles for NAS:BIOS

Headlines

Articles On GuruFocus.com
5-year lows: Elizabeth Arden Inc, Systemax Inc, BioScrip Inc, and Thompson Creek Metals Co Inc. May 26 2015 
5-year lows: Resource Capital Corp, Dynex Capital Inc, BioScrip Inc, and Kemet Corp. May 10 2015 
Two Gurus Hold Stakes in Embattled BioScrip Apr 07 2015 
A Look at Mario Gabelli's Latest Stake Increases Apr 01 2015 
Mario Gabelli Ups Stake in BioScript, But Value of Stock Declines Mar 18 2015 
A Look at Mario Gabelli's New Added Positions Feb 04 2015 
Mario Gabelli Boosts BioScrip Inc. Position Oct 28 2014 
Soros and Gabelli Top Guru Real Time Picks of the Week Aug 08 2014 
Gurus' Real Time Stock Picks of the Week May 09 2014 
Morning Coffee: Real-Time Picks May 07 2014 

More From Other Websites
Moving Average Crossover Alert: BioScrip (BIOS) Dec 01 2016
Why BioScrip (BIOS) Could Be Positioned for a Slump Nov 25 2016
BioScrip: Guidance Disappoints, Home Solutions Raises Hope Nov 17 2016
BIOSCRIP, INC. Financials Nov 16 2016
4 Companies That Destroyed Shareholders Last Week Nov 12 2016
ETF’s with exposure to BioScrip, Inc. : November 10, 2016 Nov 10 2016
Technically Speaking: BioScrip Inc (BIOS), Hertz Global Holdings, Inc (HTZ) And CVS Health Corp... Nov 09 2016
BioScrip, Inc. :BIOS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 Nov 09 2016
Edited Transcript of BIOS earnings conference call or presentation 8-Nov-16 4:00pm GMT Nov 08 2016
BioScrip Falls on Weak Earnings and Guidance Nov 08 2016
BioScrip (BIOS): Q3 Loss Narrows Y/Y, Sales Beat Estimates Nov 08 2016
BIOSCRIP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in... Nov 08 2016
BioScrip reports 3Q loss Nov 08 2016
BioScrip reports 3Q loss Nov 08 2016
BioScrip Reports Third Quarter 2016 Financial Results Nov 07 2016
Q3 2016 BioScrip Inc Earnings Release - After Market Close Nov 07 2016
BIOSCRIP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Nov 03 2016
BioScrip, Inc. breached its 50 day moving average in a Bearish Manner : BIOS-US : October 28, 2016 Oct 28 2016
Daily Wrap: The Biggest Hedge Fund Moves of the Day Oct 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)